Diagnostic performance and impact of routinely implemented Xpert® MTB/RIF assay in a setting of high incidence of drug-resistant TB in Odessa Oblast, Ukraine.

[1]  B. Molina-Moya,et al.  Tackling the MDR-TB epidemic in Ukraine: every little helps … and much more needed. , 2018, Journal of public health.

[2]  D. Cirillo,et al.  Alarming levels of multidrug-resistant tuberculosis in Ukraine: results from the first national survey. , 2018, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[3]  S. Dorman,et al.  Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study , 2018, The Lancet. Infectious diseases.

[4]  J. McIntyre,et al.  The impact of implementing a Xpert MTB/RIF algorithm on drug-sensitive pulmonary tuberculosis: a retrospective analysis , 2017, Epidemiology and Infection.

[5]  N. Konduri,et al.  User experience analysis of e-TB Manager, a nationwide electronic tuberculosis recording and reporting system in Ukraine , 2017, ERJ Open Research.

[6]  Yulia V. Dubrovskaya,et al.  Tuberculosis cases caused by heterogeneous infection in Eastern Europe and their influence on outcomes. , 2017, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[7]  Natasha Rybak,et al.  Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine , 2017, BMC Infectious Diseases.

[8]  D. Alland,et al.  Performance of the G4 Xpert® MTB/RIF assay for the detection of Mycobacterium tuberculosis and rifampin resistance: a retrospective case-control study of analytical and clinical samples from high- and low-tuberculosis prevalence settings , 2016, BMC Infectious Diseases.

[9]  Alimuddin Zumla,et al.  Implementation and Operational Research: Clinical Impact of the Xpert MTB/RIF Assay in Patients With Multidrug-Resistant Tuberculosis , 2016, Journal of acquired immune deficiency syndromes.

[10]  V. Leimane,et al.  Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia , 2016, Emerging infectious diseases.

[11]  V. Nikolayevskyy,et al.  The Xpert® MTB/RIF assay in routine diagnosis of pulmonary tuberculosis: A multicentre study in Lithuania. , 2015, Respiratory medicine.

[12]  S. Pak,et al.  Correction: Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study , 2015, PloS one.

[13]  S. Pak,et al.  Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study , 2015, PloS one.

[14]  R. Kempker,et al.  A comparison of the Xpert(®) MTB/RIF and GenoType(®) MTBDRplus assays in Georgia. , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[15]  C. Lange,et al.  Multidrug-resistant tuberculosis in Ukraine at a time of military conflict. , 2015, The International Journal of Tuberculosis and Lung Disease.

[16]  M. Mendelson,et al.  False-positive Xpert(®) MTB/RIF assays and previous treatment. , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[17]  Grant Theron,et al.  Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial , 2014, The Lancet.

[18]  N. Dendukuri,et al.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults , 2014, The Cochrane database of systematic reviews.

[19]  L. Rigouts,et al.  Rifampin Heteroresistance in Mycobacterium tuberculosis Cultures as Detected by Phenotypic and Genotypic Drug Susceptibility Test Methods , 2013, Journal of Clinical Microbiology.

[20]  W. Katagira,et al.  Impact of Xpert MTB/RIF Testing on Tuberculosis Management and Outcomes in Hospitalized Patients in Uganda , 2012, PloS one.

[21]  Y. Balabanova,et al.  Performance of the GenoType® MTBDRPlus assay in routine settings: a multicenter study , 2012, European Journal of Clinical Microbiology & Infectious Diseases.

[22]  I. Marinou,et al.  Cepheid GeneXpert MTB/RIF Assay for Mycobacterium tuberculosis Detection and Rifampin Resistance Identification in Patients with Substantial Clinical Indications of Tuberculosis and Smear-Negative Microscopy Results , 2011, Journal of Clinical Microbiology.

[23]  K. Kam,et al.  Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs , 2008 .